Brimonidine Tartrate + Placebos
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Graft Versus Host Disease
Conditions
Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease
Trial Timeline
Dec 23, 2018 → Apr 30, 2020
NCT ID
NCT03591874About Brimonidine Tartrate + Placebos
Brimonidine Tartrate + Placebos is a phase 3 stage product being developed by Ocugen for Graft Versus Host Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT03591874. Target conditions include Graft Versus Host Disease, Ocular Surface Disease, oGVHD.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03591874 | Phase 3 | Terminated |
| NCT03785340 | Phase 3 | Completed |
Competing Products
20 competing products in Graft Versus Host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Prograf + Methotrexate + Cyclosporine | Astellas Pharma | Approved | 85 |
| Alefacept | Astellas Pharma | Phase 2 | 52 |
| tacrolimus | Astellas Pharma | Approved | 85 |
| Tacrolimus + Tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| Itolizumab + EQ001 Placebo | Biocon | Phase 3 | 77 |
| EQ001 + EQ001 Placebo | Biocon | Phase 1/2 | 41 |
| SHR0302 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Acalabrutinib | AstraZeneca | Phase 2 | 52 |
| Aspirin + Ticagrelor | AstraZeneca | Approved | 85 |
| Sugammadex | Merck | Approved | 85 |
| Efprezimod alfa + Methotrexate + Tacrolimus + Placebo | Merck | Phase 2 | 52 |
| Ruxolitinib | Novartis | Approved | 85 |
| Imatinib Mesylate and Nilotinib | Novartis | Phase 2 | 52 |
| Prednisone + Jakavi(ruxolitinib) + Prednisone | Novartis | Phase 2 | 52 |
| PredEver | Novartis | Phase 2 | 52 |
| Lifitegrast 5% Ophthalmic Solution + Placebo | Novartis | Phase 1 | 33 |
| Cyclosporine | Novartis | Approved | 85 |
| Everolimus + Tacrolimus + Mycophenolic acid | Novartis | Approved | 85 |
| 1 + 2 | Novartis | Approved | 85 |